Antidepressants in Pregnancy

What Did the New Study Find About Antidepressants in Pregnancy?

The latest analysis follows a long line of research attempting to disentangle whether antidepressants themselves, or the underlying maternal depression, drive observed neurodevelopmental differences in exposed children. Earlier observational studies often reported elevated rates of autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) among children of women who took selective serotonin reuptake inhibitors (SSRIs) during pregnancy. However, those signals frequently weakened or vanished when researchers used sibling-controlled designs or adjusted for maternal psychiatric history, socioeconomic factors, and other shared family characteristics.

The current findings echo conclusions from large Scandinavian registry studies and meta-analyses suggesting that confounding by indication — the fact that women taking these medications differ from those who do not in ways that independently affect child outcomes — explains much of the previously reported association. For clinicians and patients, this matters because it shifts the conversation away from blaming the medication and toward understanding that depression itself is a serious condition with its own developmental consequences when left untreated.

Why Does Untreated Maternal Depression Also Pose Risks?

Major depression during pregnancy is not a benign condition. Research consistently links untreated antenatal depression to elevated rates of preterm delivery, fetal growth restriction, gestational complications, and poorer postnatal outcomes. The biological pathways are thought to involve dysregulated cortisol, increased inflammation, and disrupted placental function. Behaviorally, depression can reduce prenatal care attendance and increase the likelihood of poor nutrition, smoking, or substance use during pregnancy — each an established risk factor for adverse fetal outcomes.

Major guideline bodies, including the American College of Obstetricians and Gynecologists (ACOG) and the UK's National Institute for Health and Care Excellence (NICE), recommend individualized risk-benefit assessment rather than blanket avoidance of antidepressants in pregnancy. For women with moderate to severe depression, the consensus is that the potential harms of untreated illness often outweigh the typically modest, and possibly confounded, risks associated with appropriately chosen medications such as sertraline or fluoxetine.

How Should Pregnant Women and Clinicians Use This Evidence?

Pregnant women already taking antidepressants are advised to consult their prescribing clinician before making any changes. Abrupt discontinuation can trigger withdrawal symptoms and relapse, which is particularly concerning given that postpartum depression affects roughly 1 in 7 women and can severely impact maternal and infant well-being. Shared decision-making should include consideration of the woman's history of depression, the severity of current symptoms, prior response to non-pharmacological treatments such as cognitive behavioral therapy or interpersonal therapy, and the specific antidepressant being considered.

For some women, psychotherapy alone may be sufficient and appropriate. For others, continuing or initiating an antidepressant during pregnancy is the clinically sound choice. The new study reinforces that the conversation should not center on fear of medication-induced harm, but on choosing the treatment plan that best supports both maternal mental health and fetal development. Ongoing research, including prospective cohort studies and sibling-controlled analyses, continues to refine our understanding of these complex trade-offs.